Work

Enhancing neuromolecular imaging classification in low-data regimes with generative machine learning: A case study in HDAC PET/MR imaging of alcohol use disorder

Year: 2025

Type: article

Abstract: Introduction Positron Emission Tomography (PET) is a vital modality for investigating brain related disorders. However, data scarcity especially for novel molecular targets like neuroepigenetic enzymes combined with difficult-to-recruit patient populations limits the development of machine learning (ML) models. Our primary objective is to enhance single-subject classification of neuromolecular imaging data and facilitate biomarker discovery. We demonstrate our approach using histone deacetylase (HDAC) PET/MR imaging in Alcohol Use Disorder (AUD). Methods We propose Catalysis Training pipeline , a framework that augments real imaging data with high-quality synthetic data generated by a Wasserstein Conditional Generative Adversarial Network (WCGAN). Using [ 11 C]Martinostat PET/MR imaging, we extracted 1-D standardized uptake value ratio (SUVR) tabular features representing HDAC enzyme expression density across eight cingulate subregions. These were used to train and test ML classifiers, including Support Vector Machine (SVM), XGBoost, and Random Forest, under leave-one-out cross-validation. Results Integrating synthetic data in the training process improved classification accuracy significantly: +26% for XGBoost and Random Forest (from 59% to 85%), and +18% for SVM (from 70% to 88%). Synthetic samples improved model generalizability. Key hemispheric and subregional cingulate HDAC patterns were also identified as potential biomarkers. Conclusion Our results demonstrate that generative AI can help overcome data scarcity in low-data regime neuroimaging applications. Catalysis Training provides a scalable strategy to enhance ML-driven biomarker discovery and disease classification, especially for rare or difficult-to-study disorders like AUD. Clinically, cingulate HDAC expression measured by [ 11 C]Martinostat PET/MR shows promise as an objective biomarker for AUD, complementing DSM-based diagnosis and informing novel treatment strategies.

Source: Neuroscience Informatics

DOI: 10.1016/j.neuri.2025.100225